Insight Molecular Diagnostics Inc. — Director's Dealing 2017

Feb 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2017-02-17

Reporting Person: ANNETT WILLIAM (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-17	Option to Purchase Common Stock	$4.70	A	225000	Acquired	2027-02-16	Common Stock (225000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$3.06	2026-02-15	Common Stock (250000)	250000	Direct
Option to Purchase Common Stock	$2.20	2025-06-15	Common Stock (605000)	605000	Direct
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (5000)	5000	Direct

Footnotes

F1: One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.

F2: One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

F3: One quarter of the options vested on June 15, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

F4: Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.